NCT02178306View on ClinicalTrials.gov

Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis

PHASE4CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

April 30, 2002

Conditions
Hypertension
Interventions
DRUG

Telmisartan low dose

DRUG

Telmisartan high dose

patients switch to high dose if mean SBP \>= 85 mmHg after 4 weeks of treatment

DRUG

Placebo

Run-in phase

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY